Abstract
Although the incidence of gastric cancer has decreased since 1930, it continues to be a significant health problem. Surgical resection is the mainstay treatment of resectable gastric adenocarcinoma. Although the survival rate of patients with early gastric cancer is high, these patients are less than 20% of all gastric cancer patients. The prognosis of locally advanced or metastatic disease is poor. Several recent clinical studies have proven the efficacy of chemotherapy or chemo-radiotherapy in gastric cancer. Despite chemotherapy in metastastic gastric cancer is essentially palliative, several randomized trials have shown that chemotherapy confers a survival advantage. The randomized trial (INT016) of post operative chemo-radiotherapy in patients with localized advanced gastric cancer showed promising result. Another research direction of gastric cancer is preoperative radiotherapy or chemoradiotherapy, and the results of several clinical trials showed the increasing resectable rate and survival benefit. However, there was no strong evidence of post operative chemotherapy in treatment of resectable gastric cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
